Rob Dillard

DocwireNews

A recent study suggested that fruquintinib combined with the anti-programmed death-1 (PD-1) antibody toripalimab has a better effect compared with fruquintinib alone in the third-line treatment of patients with refractory metastatic colorectal cancer (mCRC). The results <a href="https://pubmed.ncbi.nlm.nih.gov/37201046/">appeared</a> in the Journal of Gastrointestinal Oncology.
In this single-arm, single-center, prospective, phase 2 clinical trial, researchers assessed 19 Chinese microsatellite stabilized (MSS) patients (median age, 52 years) with refractory or advanced mCRC. The trial population received fruquintinib (5 mg orally once daily for 3 weeks followed by 1 week off in 4-week cycles) plus toripalimab (240 mg intravenously administered on day 1 once every 3 weeks). The respective treatments were administered until disease progression or unacceptable toxicity. In addition to toxicity, investigators analyzed the objective response rate (ORR), progression-free survival (PFS), overall survival (OS), 1-year PFS rate, and disease control rate.
Their findings showed that approximately 21% of patients achieved a partial response, more than 52% experienced stable disease, and around 21% experienced progressive disease. The ORR was observed to be 21.05%, while median PFS and OS were 5.98 months and 11.10 months, respectively. The treatment combination yielded greater PFS in patients with peritoneal metastasis. The investigators noted that the most common treatment-related adverse reactions were fatigue (57.89%), hepatic dysfunction (42.11%), and hypertension (36.84%). No serious adverse effects or adverse effect-related deaths were reported in this trial.
“Our study provides evidence supporting fruquintinib combined with an anti-PD-1 monoclonal antibody [has] the better effect than fruquintinib alone in the third-line setting for Chinese patients with MSS advanced colorectal cancer. Primary lesion excision and peritoneal metastasis were independent prognostic factors of PFS,” the investigators concluded, though they noted that further “well-designed, prospective, large-scale studies are needed to validate this outcome.”

The Combination of Tucatinib and Alpelisib Shows Efficacy in Patients with HER2-positive Metastatic Breast Cancer

SABCS 2024

Laura Litwin

How Socioeconomic Deprivation Affects Health Care, Surgical Outcomes for US Veterans With NSCLC

Non-Small Cell Lung Cancer

Emily Menendez

SPOTLIGHT, GLOW Trials Lead to FDA Approval of Zolbetuximab-clzb With Chemotherapy for Gastric/GEJ Cancer

Gastroesophageal Cancer

Latest News

Fruquintinib Plus Toripalimab Is an Effective Third-line Treatment of Advanced Colorectal Cancer

Colorectal Cancer

Fruquintinib combined with the anti-programmed death-1 antibody toripalimab is effective in treating advanced colon cancer.

Fruquintinib Plus Toripalimab Is an Effective Third-Line Treatment of Advanced Colorectal Cancer

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe